U.S. House Energy & Commerce Committee Democratic leaders have sent letters to three major drug manufacturers demanding an explanation for the skyrocketing price of insulin. The E&C Committee has jurisdiction over the 340B program and plays an instrumental role on drug pricing policy.
E&C full committee chair Frank Pallone (D-N.J.) and Oversight and Investigations subcommittee chair Diana DeGette (D-Colo.) sent the letters to insulin manufacturers Eli Lilly, Novo Nordisk, and Sanofi last week. Pallone and DeGette sent the three companies letters in January 2019 requesting information on the root causes of the rising cost of insulin. DeGette’s subcommittee health a hearing on insulin affordability three months later.
U.S. House Energy & Commerce Committee Democratic leaders have sent letters to three major drug manufacturers demanding an explanation for the skyrocketing price of insulin. The E&C Committee has jurisdiction over the 340B program and plays an instrumental role on drug pricing policy.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.